Integration of Single Pass Tangential Flow Filtration and High Performance Countercurrent Membrane Purification for Intensification of Monoclonal Antibody Processing
IF 3.6 2区 生物学Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Mirko Minervini, Aylin Mohammadzadehmarandi, Ali Behboudi, Sheldon F. Oppenheim, Andrew L. Zydney
{"title":"Integration of Single Pass Tangential Flow Filtration and High Performance Countercurrent Membrane Purification for Intensification of Monoclonal Antibody Processing","authors":"Mirko Minervini, Aylin Mohammadzadehmarandi, Ali Behboudi, Sheldon F. Oppenheim, Andrew L. Zydney","doi":"10.1002/bit.29038","DOIUrl":null,"url":null,"abstract":"<p>There is increasing interest in the development of intensified processes that can provide significant reductions in manufacturing costs for monoclonal antibody (mAb) products. This study examines the performance of an integrated membrane process that combines single-pass tangential flow filtration (SPTFF) with high-performance countercurrent membrane purification (HPCMP) for the preconditioning of clarified culture fluid (CCF). The SPTFF step was operated with a single-pass concentration factor of 20x for 24 h filtration, with no evidence of membrane fouling; the transmembrane pressure remained < 30 kPa throughout the process. HPCMP was then performed on the pre-concentrated feed, resulting in a 60 ± 8% reduction in host cell proteins (HCPs) and more than a 30-fold removal of DNA while maintaining 94 ± 3% mAb step yield. The HPCMP process operated continuously for 36 h with a slight decline in HCP removal in the latter stages of operation due to membrane fouling. The buffer requirement for the integrated process was only 76 L/kg mAb. These results demonstrate the potential of using an integrated SPTFF-HPCMP process for preconditioning CCF as part of a highly intensified mAb manufacturing process with much lower cost of goods.</p>","PeriodicalId":9168,"journal":{"name":"Biotechnology and Bioengineering","volume":"122 9","pages":"2410-2419"},"PeriodicalIF":3.6000,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/bit.29038","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biotechnology and Bioengineering","FirstCategoryId":"5","ListUrlMain":"https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/bit.29038","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
There is increasing interest in the development of intensified processes that can provide significant reductions in manufacturing costs for monoclonal antibody (mAb) products. This study examines the performance of an integrated membrane process that combines single-pass tangential flow filtration (SPTFF) with high-performance countercurrent membrane purification (HPCMP) for the preconditioning of clarified culture fluid (CCF). The SPTFF step was operated with a single-pass concentration factor of 20x for 24 h filtration, with no evidence of membrane fouling; the transmembrane pressure remained < 30 kPa throughout the process. HPCMP was then performed on the pre-concentrated feed, resulting in a 60 ± 8% reduction in host cell proteins (HCPs) and more than a 30-fold removal of DNA while maintaining 94 ± 3% mAb step yield. The HPCMP process operated continuously for 36 h with a slight decline in HCP removal in the latter stages of operation due to membrane fouling. The buffer requirement for the integrated process was only 76 L/kg mAb. These results demonstrate the potential of using an integrated SPTFF-HPCMP process for preconditioning CCF as part of a highly intensified mAb manufacturing process with much lower cost of goods.
期刊介绍:
Biotechnology & Bioengineering publishes Perspectives, Articles, Reviews, Mini-Reviews, and Communications to the Editor that embrace all aspects of biotechnology. These include:
-Enzyme systems and their applications, including enzyme reactors, purification, and applied aspects of protein engineering
-Animal-cell biotechnology, including media development
-Applied aspects of cellular physiology, metabolism, and energetics
-Biocatalysis and applied enzymology, including enzyme reactors, protein engineering, and nanobiotechnology
-Biothermodynamics
-Biofuels, including biomass and renewable resource engineering
-Biomaterials, including delivery systems and materials for tissue engineering
-Bioprocess engineering, including kinetics and modeling of biological systems, transport phenomena in bioreactors, bioreactor design, monitoring, and control
-Biosensors and instrumentation
-Computational and systems biology, including bioinformatics and genomic/proteomic studies
-Environmental biotechnology, including biofilms, algal systems, and bioremediation
-Metabolic and cellular engineering
-Plant-cell biotechnology
-Spectroscopic and other analytical techniques for biotechnological applications
-Synthetic biology
-Tissue engineering, stem-cell bioengineering, regenerative medicine, gene therapy and delivery systems
The editors will consider papers for publication based on novelty, their immediate or future impact on biotechnological processes, and their contribution to the advancement of biochemical engineering science. Submission of papers dealing with routine aspects of bioprocessing, description of established equipment, and routine applications of established methodologies (e.g., control strategies, modeling, experimental methods) is discouraged. Theoretical papers will be judged based on the novelty of the approach and their potential impact, or on their novel capability to predict and elucidate experimental observations.